194 related articles for article (PubMed ID: 29400013)
21. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
Hoang LN; Han G; McConechy M; Lau S; Chow C; Gilks CB; Huntsman DG; Köbel M; Lee CH
Histopathology; 2014 Mar; 64(4):585-96. PubMed ID: 24103020
[TBL] [Abstract][Full Text] [Related]
22. IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA.
Socolov D; Socolov R; Lupascu IA; Rugina V; Gabia O; Garauleanu DM; Carauleanu A
Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):355-62. PubMed ID: 27483717
[TBL] [Abstract][Full Text] [Related]
23. A report of two cases of dedifferentiated endometrioid carcinoma: A newly described underrecognized tumor of poor prognosis.
Boler AK; Akhtar S; Bandyopadhyay A; Roy S
Indian J Pathol Microbiol; 2020 Feb; 63(Supplement):S91-S93. PubMed ID: 32108637
[TBL] [Abstract][Full Text] [Related]
24. Coexistence of endometrial mesonephric-like adenocarcinoma and endometrioid carcinoma suggests a Müllerian duct lineage: a case report.
Yano M; Shintani D; Katoh T; Hamada M; Ito K; Kozawa E; Hasegawa K; Yasuda M
Diagn Pathol; 2019 Jun; 14(1):54. PubMed ID: 31174566
[TBL] [Abstract][Full Text] [Related]
25. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?
Silva EG; Deavers MT; Bodurka DC; Malpica A
Int J Gynecol Pathol; 2006 Jan; 25(1):52-8. PubMed ID: 16306785
[TBL] [Abstract][Full Text] [Related]
26. Immunophenotypic features of dedifferentiated endometrial carcinoma - insights from BRG1/INI1-deficient tumours.
Hoang LN; Lee YS; Karnezis AN; Tessier-Cloutier B; Almandani N; Coatham M; Gilks CB; Soslow RA; Stewart CJ; Köbel M; Lee CH
Histopathology; 2016 Oct; 69(4):560-9. PubMed ID: 27101785
[TBL] [Abstract][Full Text] [Related]
27. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
28. Endometrioid carcinoma of the endometrium with an invasive component of minimal deviation carcinoma.
Mai KT; Perkins DG; Yazdi HM; Thomas J
Hum Pathol; 2002 Aug; 33(8):856-8. PubMed ID: 12203221
[TBL] [Abstract][Full Text] [Related]
29. Panel of Villin, Pro-Ex-C, Estrogen Receptor and Progesterone Receptor Expressions Could Help in Differentiation Between Endocervical and Endometrioid Adenocarcinoma.
Elfeky M; Harb O; Gertallah L
Turk Patoloji Derg; 2017; 1(1):29-40. PubMed ID: 28832070
[TBL] [Abstract][Full Text] [Related]
30. [Expression of ARID1A in ovarian seromucinous neoplasms and its clinicopathological significance].
Ding XH; Tian X; Wang LQ; Wang Y; Liu AJ
Zhonghua Bing Li Xue Za Zhi; 2020 Jun; 49(6):588-593. PubMed ID: 32486536
[No Abstract] [Full Text] [Related]
31. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint.
Kamoi S; AlJuboury MI; Akin MR; Silverberg SG
Int J Gynecol Pathol; 2002 Jul; 21(3):217-23. PubMed ID: 12068166
[TBL] [Abstract][Full Text] [Related]
32. Sertoliform endometrioid carcinoma of the endometrium with dual immunophenotypes for epithelial membrane antigen and inhibin alpha: case report and literature review.
Liang SX; Patel K; Pearl M; Liu J; Zheng W; Tornos C
Int J Gynecol Pathol; 2007 Jul; 26(3):291-7. PubMed ID: 17581414
[TBL] [Abstract][Full Text] [Related]
33. [Endometrial carcinomas and precursor lesions--new aspects].
Schmidt D
Pathologe; 2009 Jul; 30(4):261-7. PubMed ID: 19495762
[TBL] [Abstract][Full Text] [Related]
34. Synchronous endometrial and ovarian carcinomas: predictors of risk and associations with survival and tumor expression profiles.
Kelemen LE; Rambau PF; Koziak JM; Steed H; Köbel M
Cancer Causes Control; 2017 May; 28(5):447-457. PubMed ID: 28194593
[TBL] [Abstract][Full Text] [Related]
35. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
[TBL] [Abstract][Full Text] [Related]
36. Morules in endometrioid proliferations of the uterus and ovary consistently express the intestinal transcription factor CDX2.
Houghton O; Connolly LE; McCluggage WG
Histopathology; 2008 Aug; 53(2):156-65. PubMed ID: 18752499
[TBL] [Abstract][Full Text] [Related]
37. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract][Full Text] [Related]
38. Primary Endometrial Yolk Sac Tumor With Endodermal-Intestinal Differentiation Masquerading as Metastatic Colorectal Adenocarcinoma.
Damato S; Haldar K; McCluggage WG
Int J Gynecol Pathol; 2016 Jul; 35(4):316-20. PubMed ID: 26598980
[TBL] [Abstract][Full Text] [Related]
39. Synchronous ovarian endometrioid adenocarcinoma with a functioning stroma and endometrial endometrioid adenocarcinoma by different loss of heterozygosity findings.
Takai N; Kai K; Tsuno A; Nasu K; Kashima K; Narahara H
Arch Gynecol Obstet; 2011 Oct; 284(4):951-5. PubMed ID: 21046134
[TBL] [Abstract][Full Text] [Related]
40. GLUT-1 Expression in Proliferative Endometrium, Endometrial Hyperplasia, Endometrial Adenocarcinoma and the Relationship Between GLUT-1 Expression and Prognostic Parameters in Endometrial Adenocarcinoma.
Canpolat T; Ersöz C; Uğuz A; Vardar MA; Altintaş A
Turk Patoloji Derg; 2016; 32(3):141-7. PubMed ID: 27562387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
